AstraZeneca Acquires Asian Rights To Cubist's Antibiotic Cubicin
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca acquired Asian rights to Cubist's antibiotic Cubicin (daptomycin), but the deal does not include Japan, Cubist announced Dec. 4